Ada Health to raise $90 million in a round led by Leaps by Bayer.

Ada Health GmbH, a Berlin, Germany-based digital health company, announced completing a $90 million Series B investment round.

The money was raised from investors led by Leaps by Bayer, the impact investment arm of Bayer AG, joined by Samsung Catalyst Fund, Vitruvian Partners, Inteligo Bank, F4 and Mutschler Ventures.

The investment will help advance Ada's popular health assessment technology, enabling the digital health pioneer to accelerate its path towards becoming the world's leading personalized operating system for health, as well as to further grow the company's leading position in the United States.

In addition to the finance backing, Bayer and Ada Health are in discussions about entering into a longer-term strategic partnership to support the company's healthcare businesses.

Ada Health, founded in 2011 by Claire Novorol, Daniel Nathrath (CEO) and Martin Hirsch, developed a powerful AI-based health assessment and care navigation platform that helps users to understand their symptoms, to identify and differentiate conditions with a high degree of medical accuracy, and to navigate safely to the right care, at the right time.

The Ada platform has over 11 million users worldwide and has completed over 23 million assessments since its global launch in 2016.